<DOC>
	<DOC>NCT01318421</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.</brief_summary>
	<brief_title>A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>This study is open only to subjects who have completed the week 12 visit in study ELND002MS103 while taking their assigned dose of study drug. Subject has no new medical contraindications to continue participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Relapsing forms of secondary progressive multiple sclerosis (SPMS)or relapsing-remitting multiple sclerosis (RRMS)</keyword>
</DOC>